Anteris Technologies cements position as serious player in TAVR market with in-vivo demonstration of ComASUR™ Transfemoral Delivery System
- Anteris Technologies extends manufacturing agreement with LeMaitre for CardioCel™ and VascuCel™
- Anteris Technologies' ADAPT® conduit proof of concept animal study finds no calcification in carotid artery
- Anteris Technologies 'sitting on a significantly large opportunity' as it moves into FDA studies
Quick facts: Anteris Technologies Ltd
Price: 8.23 AUD
Market Cap: $66.34 m
About the company
Anteris Technologies Ltd (ASX:ARV) (OTCMKTS:AMEUF) (FRA:DDF) is a structural heart company delivering clinically superior and durable solutions through better science and better design.
Its focus is on developing next-generation technologies that help healthcare professionals create life-changing outcomes for patients.
The Anteris’ DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.
How it is doing
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF, FRA:DDF) has signed a further agreement with LeMaitre Vascular Inc to extend the manufacturing of CardioCel™ and VascuCel™ at its Malaga facility in Western Australia.
The agreement includes a nine-month extension to the current manufacturing contract, which will now conclude in July 2023.
Anteris will continue to receive existing agreed pricing over the extension period amended to remove the foreign exchange risk.
It also continues to retain sole control of the entire IP portfolio for ADAPT®, the tissue technology on which the company’s DurAVR™ single-piece 3D aortic valve is built, which is licensed to LeMaitre for specified fields of use.
The company plans to use proceeds from the placement in meeting the working capital requirements of DurAVR™, the company’s 3D single-piece aortic valve for the treatment of aortic stenosis.
Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF, FRA:DDF) has been granted a patent for its ‘Sterilized packaging system for catheter’ invention by the Commonwealth of Australia Patent Office on July 22, 2021
Sterilization of surgical products used in vivo is essential, and having a specialised, proprietary sterilization system enhances the intellectual property barrier around Anteris’ key technologies particularly for its ComASUR transfemoral delivery system and maintains product sterile status in the delivery chain from manufacturing point to surgical theatre.
Insight: Anteris Technologies' ADAPT® conduit proof of concept animal study finds no...
Anteris Technologies Ltd (ASX:AVR) (FRA:DDF) has completed a Proof of Concept (POC) animal study testing the viability of ADAPT® treated conduits in the carotid artery, with conduits treated showing no evidence of calcification, as indicated by histopathology.
In addition, there were no visible signs of inflammation, specifically in the intimal or medial layers of the conduits and the grafts also showed the presence of a partial neo-intimal layer, likely indicating surface remodelling of the vessels.
What management says
It's recently achieved a breakthrough in manufacturing the tissue used in ADAPT® treated products from bovine pericardium, after developing specialised machinery to create consistently thin tissue through an innovative processing technique.
''It's important to me to get the point across that the product is coming to market'', he says.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE